Puma Biotechnology (PBYI) Non-Current Debt (2011 - 2025)
Puma Biotechnology's (PBYI) quarterly Non-Current Debt came in at $10.9 million in Q2 2025, down 75.15% YoY from $43.7 million in Q2 2024, and up 2.09% on a QoQ basis from $10.6 million in Q1 2025.
Puma Biotechnology (PBYI) Non-Current Debt (2011 - 2025) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of Non-Current Debt data on file, last reported at $10.9 million in Q2 2025.
- Quarterly Non-Current Debt fell 75.15% year-over-year to $10.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $10.9 million (down 75.15% YoY) and the FY2024 annual result came in at $21.7 million, down 66.92% from the prior year.
- Non-Current Debt advanced to $10.9 million in Q2 2025, from $10.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $98.6 million in Q1 2023 to a low of $10.6 million in Q1 2025.
- A 5-year average of $68.5 million and a median of $76.5 million in 2021 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt jumped 42.17% — and 2025, when it tumbled 80.53%.
- Tracing PBYI's Non-Current Debt over 5 years: stood at $97.1 million in 2021, then rose by 1.25% to $98.3 million in 2022, then tumbled by 33.21% to $65.7 million in 2023, then slumped by 66.92% to $21.7 million in 2024, then plunged by 49.96% to $10.9 million in 2025.
- The last three Non-Current Debt figures came in at $10.9 million (Q2 2025), $10.6 million (Q1 2025), and $21.7 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 10.87 Mn |
| Mar 31, 2025 | 10.65 Mn |
| Dec 31, 2024 | 21.72 Mn |
| Sep 30, 2024 | 32.75 Mn |
| Jun 30, 2024 | 43.74 Mn |
| Mar 31, 2024 | 54.69 Mn |
| Dec 31, 2023 | 65.66 Mn |
| Sep 30, 2023 | 76.63 Mn |
| Jun 30, 2023 | 87.62 Mn |
| Mar 31, 2023 | 98.62 Mn |
| Dec 31, 2022 | 98.31 Mn |
| Sep 30, 2022 | 97.99 Mn |
| Jun 30, 2022 | 97.68 Mn |
| Mar 31, 2022 | 97.38 Mn |
| Dec 31, 2021 | 97.09 Mn |
| Sep 30, 2021 | 96.80 Mn |
| Jun 30, 2021 | 68.71 Mn |
| Mar 31, 2021 | 76.35 Mn |
| Dec 31, 2020 | 84.03 Mn |
| Sep 30, 2020 | 91.71 Mn |